GlassScriptPhysician profile
Javi A Mashettiwar
NPI 1306371109
$3,165.63
in general payments reported to CMS, 2019-2025
24 companies · $740 in 2025
The $740 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $135 · 2023: $708 · 2024: $1,477 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $782.98 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $333.38 | 2022-2025 | Airsupra, Breztri |
| Amgen INC. | $298.30 | 2021-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $296.58 | 2023-2025 | |
| Lilly USA, LLC | $271.85 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $201.55 | 2023-2025 | |
| Glaxosmithkline, LLC. | $178.11 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.12 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $115.62 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $83.21 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $78.96 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $72.34 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $54.02 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $51.71 | 2023-2025 | Freestyle Libre 3 |
| Bausch Health US, LLC | $41.76 | 2023 | Wellbutrin, Aplenzin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $36.89 | 2023-2024 | Heplisav-B |
| Azurity Pharmaceuticals, INC. | $30.47 | 2023 | Edarbi, Horizant |
| Almatica Pharma LLC | $28.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.98 | 2021 | |
| Alk-Abello, INC | $15.87 | 2025 | Neffy, Grastek, Odactra |
| Arbor Pharmaceuticals, INC. | $15.62 | 2021 | |
| Neurocrine Biosciences, INC. | $15.00 | 2022 | |
| Biogen, INC. | $13.44 | 2021 | |
| Phadia US INC. | $12.78 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javi Mashettiwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.